Amneal Pharmaceuticals (AMRX) investor relations material

Strategic positioning and recent acquisition

• Announced acquisition of Kashiv BioSciences, vertically integrating the biosimilars business and expanding the pipeline to 20 biosimilars, with multiple manufacturing and R&D sites in the US and India.

• Hormonal and pain patches are driving significant in-line product growth, with capacity being rapidly expanded to meet rising demand.

• Forecasts a major increase in estrogen patch usage among women aged 45-65, with capacity expected to triple or quadruple by August.

Biosimilars market outlook and growth drivers

• Biosimilars market is shifting toward private label and PBM channels, with fewer competitors and a focus on niche products with less than four competitors.

• Regulatory changes have reduced development time and costs, making biosimilars more attractive and enabling faster market entry.

• Projects biosimilars to reach 70%-80% market share of total volume, with volume expansion driven by private label and buy-and-build strategies.

• Long-term guidance includes $1.2 billion in biosimilar revenues by 2030, with key products like XOLAIR, Orencia, and Nplate contributing significantly.

Commercial and specialty business momentum

• Affordable medicines segment is expanding, with launches in respiratory, long-acting depot, and hospital products, including FDA-approved 505(b)(2) products.

• Small molecule launches, such as lanreotide and iohexol, are expected to be significant, with limited competition and dedicated facilities.

• Specialty segment highlights strong growth for CREXONT and Brekiya, with CREXONT aiming for first-line therapy status in Parkinson’s and international expansion.

• Brekiya’s auto-injector for migraines and cluster headaches is expected to double initial revenue targets due to high demand and patient benefit.